 |
Vol.63 No.2 contents | Japanese/English |
 | Full Text of PDF (725K) Article in Japanese |
- Original Article -
Predictive Biomarkers of Immune Checkpoint Inhibitors Plus Platinum-based Chemotherapy for Non-small-cell Lung Cancer
Shinji Kakumoto1,2, Yusuke Takayama1, Ren Seike1, Jun Yano1, Shohei Mishima1, Hiroyasu Shoda11Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Japan, 2Department of Medicine, Hiroshima City Funairi Citizens Hospital, Japan
Background/Aim. Immune checkpoint inhibitors (ICIs) plus platinum-based chemotherapy is the recommended first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, which biomarkers are useful for predicting the efficacy of ICIs plus chemotherapy is unclear. We therefore explored biomarkers that may predict the progression-free survival (PFS) following treatment with ICIs plus chemotherapy. Patients and Methods. We retrospectively reviewed 85 patients with NSCLC who received ICIs plus platinum-based chemotherapy between January 2019 and July 2021. The association between biomarkers and the effect of the therapy on the PFS was investigated. Results. Multivariable COX regression analyses revealed that a pretreatment modified Glasgow prognostic score (mGPS) of 2 (hazard ratio [HR]: 1.76, p=0.004), an albumin-globulin ratio (AGR) <1.4 (HR: 2.57, p=0.016), and an advanced lung cancer inflammation index (ALI) <10.1 (HR: 2.20, p=0.041) were associated with a poor PFS. Conclusion. The mGPS, AGR, and ALI may be useful predictive factors for ICIs plus platinum-based chemotherapy in NSCLC.
key words: Non-small-cell lung cancer, Biomarker, Combined immunotherapy
Received: June 21, 2022
Accepted: October 5, 2022
JJLC 63 (2): 84-90, 2023
